Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells. (2nd December 2017)

• Record Type: Journal Article
• Authors: He, Jian; Zheng, Rong; Zhang, Zhenghua; Tan, Jie; Zhou, Chaofan; Zhang, Guoqing; Jiang, Xinglu; Sun, Qianyi; Zhou, Sufang; Zheng, Duo; Huang, Yong; Wu, Lige; Lai, Zongqiang; Li, Jieping; Yang, Nuo; Lu, Xiaoling; Zhao, Yongxiang
• Is Part Of: Oncoimmunology. Volume 6:Number 12(2017)
• Publication Date: 2017-12-02
• Subjects: Dendritic cells -- Tumor cells -- Fusion cells -- Collagen I -- Immunotherapy; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2017.1361094
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Low fusion efficiency and nominal activity of fusion cells (FCs) restrict the clinical application of dendritic cell (DC)/tumor fusion cells. Collagen I (Col I) is an interstitial collagen with a closely-knit structure used to repair damaged cell membranes. This study evaluated whether Col I could improve the fusion efficiency of polyethylene glycol (PEG)-induction and enhance the immunogenicity of fusion vaccine. DC/B16 melanoma and controlled DC/H22 hepatoma cell fusions were induced by PEG with or without Col I. Col I/PEG treatment increased the levels of DC surface molecules and the secretion of lactate, pro- and anti-inflammatory cytokines in fusion cells. Col I/PEG-treated FCs enhanced T-cell proliferation and cytotoxic T lymphocyte activity. The Col I-prepared fusion vaccine obviously suppressed tumor growth and prolonged mice survival time. Thus Col I treatment could significantly improve the efficiency of PEG-induced DC/tumor fusion and enhance the anticancer activity of the fusion vaccine. This novel fusion strategy might promote the clinical application of DC/tumor fusion immunotherapy.